Current practices for the management of Barrett's esophagus (BE) vary across Europe, as several national European guidelines exist.This Position Statement from the European Society of Gastrointestinal Endoscopy (ESGE) is an attempt to homogenize recommendations and, hence, patient management according to the best scientific evidence and other considerations (e.g. health policy). A Working Group developed consensus statements, using the existing national guidelines as a starting point and considering new evidence in the literature. The Position Statement wishes to contribute to a more cost-effective approach to the care of patients with BE by reducing the number of surveillance endoscopies for patients with a low risk of malignant progression and centralizing care in expert centers for those with high progression rates. MAIN STATEMENTS MS1The diagnosis of BE is made if the distal esophagus is lined with columnar epithelium with a minimum length of 1 cm (tongues or circular) containing specialized intestinal metaplasia at histopathological examination. MS2The ESGE recommends varying surveillance intervals for different BE lengths. For patients with an irregular Z-line/columnarlined esophagus of < 1 cm, no routine biopsies or endoscopic surveillance is advised. For BE ≥ 1 cm and < 3 cm, BE surveillance should be repeated every 5 years. For BE ≥ 3 cm and < 10 cm, the interval for endoscopic surveillance should be 3 years. Patients with BE with a maximum extent ≥ 10 cm should be referred to a BE expert center for surveillance endoscopies. Patients with limited life expectancy and advanced age should be discharged from endoscopic surveillance. MS3The diagnosis of any degree of dysplasia (including "indefinite for dysplasia") in BE requires confirmation by an expert gastrointestinal pathologist. MS4Patients with visible lesions in BE diagnosed as dysplasia or early cancer should be referred to a BE expert center. All visible abnormalities, regardless of the degree of dysplasia, should be removed by means of endoscopic resection techniques in order to obtain optimal histopathological staging MS5 All patients with a BE ≥ 10 cm, a confirmed diagnosis of low grade dysplasia, high grade dysplasia (HGD), or early cancer should be referred to a BE expert center for surveillance and/or treatment.BE expert centers should meet the following criteria: annual case load of ≥10 new patients undergoing endoscopic treatment for HGD or early carcinoma per BE expert endoscopist; endoscopic and histological care provided by endoscopists and pathologists who have followed additional training; at least 30 supervised endoscopic resection and 30 endoscopic ablation procedures to acquire competence in technical skills, management pathways, and complications; multidisciplinary meetings with gastroenterologists, surgeons, oncologists, and pathologists to discuss patients with Barrett's neoplasia; access to experienced esophageal surgery; and all BE patients registered prospectively in a database. Position statementAppendix e1 -e4Onli...

trialregister.nl Identifier: NTR1198.

mon and potentially lethal disorder. 1 In the United States alone, more than 50 000 patients are admitted with acute pancreatitis each year. 2 One of the most dreaded complications in these patients is infected necrotizing pancreatitis that leads to sepsis and is often followed by multiple organ failure. 3 In these patients interventions are necessary to debride the infected necrosis, but the interventions themselves cause substantial morbidity. 4-6 The treatment of infected necrotizing pancreatitis has undergone fundamental changes in recent years. Whenever possible, intervention is postponed until the collections with necrosis are demarcated. 7,8 Demarcation facilitates necrosectomy and reduces complications related to the drainage and debride-ment procedures. 9 A recent randomized trial demonstrated that a step-up approach of percutaneous catheter For editorial comment see p 1084.

No abstract

Fasting instructions prior to UGI endoscopy Minimum 7-minute procedure time for first diagnostic UGI endoscopy and follow-up of gastric intestinal metaplasia Documentation of procedure duration Minimum 1-minute inspection time per cm circumferential Barrett's epithelium Accurate photodocumentation of anatomical landmarks and abnormal findings Use of Lugol chromoendoscopy in patients with a curatively treated ENT or lung cancer to exclude a second primary esophageal cancer Accurate application of standardized disease-related terminology Application of validated biopsy protocol to detect gastric intestinal metaplasia (MAPS guidelines) Application of Seattle protocol in Barrett's surveillance Prospective registration of Barrett's patients Accurate registration of complications after therapeutic UGI endoscopy UGI, upper gastrointestinal; ENT, ear, nose, and throat; MAPS, management of patients with precancerous conditions and lesions of the stomach.